Vinblastine, Bleomycin, and Methotrexate Chemotherapy Plus Extended-Field Radiotherapy in Early, Favorably Presenting, Clinically Staged Hodgkin's Patients: The Gruppo Italiano per lo Studio dei Linfomi Experience

Paolo G. Gobbi, Carlo Pieresca, Antonio Frassoldati, Mario Carotenuto, Nicola Di Renzo, Antonio La Sala, Raffaella Bertè, Paolo Avanzini, Massimo Federico, Vittorio Silingardi, Edoardo Ascari

Research output: Contribution to journalArticle

Abstract

Purpose: To ascertain whether vinblastine, bleomycin, and methotrexate (VBM) (CT) combined with extended-field radiotherapy (EF RT) is effective enough to spare laparotomy in early, favorably presenting Hodgkin's disease (HD) patients. Patients and Methods: Fifty patients with clinical stage IA or IIA HD with favorable histology and no bulky masses entered a prospective multicenter study started in January 1988. The median follow-up time was 38 months. Results: All patients achieved a complete remission (CR). Five relapsed after 3 to 40 months and underwent successful salvage therapy. The actuarial remission rate was 0.89% at 3 years and 0.82% at 5 years. Two patients died in CR: one of severe pulmonary toxicity, the other of a second neoplasia (adenocarcinoma of the lung), 2 and 43 months after the end of therapy, respectively. The hematologic toxicity recorded during VBM CT was mild on the whole. Major toxicity was represented by pulmonary side effects and neurologic symptoms. Multiple regression analysis demonstrated that pulmonary toxicity was significantly related only to the amount of RT delivered to the mediastinum and not to the relative dose of bleomycin, to the dose-intensities of the three drugs in the regimen, or to patient age or sex. The same statistical technique showed that the only clinical factor related to grade of neurotoxicity was vinblastine dosage. Conclusion: VBM CT combined with EF RT is an effective treatment for early, clinically staged, favorable HD patients. However, the toxicity of this combination suggests that certain modifications should be evaluated.

Original languageEnglish
Pages (from-to)527-533
Number of pages7
JournalJournal of Clinical Oncology
Volume14
Issue number2
Publication statusPublished - Feb 1996

Fingerprint

Vinblastine
Bleomycin
Hodgkin Disease
Methotrexate
Radiotherapy
Drug Therapy
Lung
Salvage Therapy
Mediastinum
Neurologic Manifestations
Laparotomy
Multicenter Studies
Histology
Regression Analysis
Prospective Studies
Therapeutics
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vinblastine, Bleomycin, and Methotrexate Chemotherapy Plus Extended-Field Radiotherapy in Early, Favorably Presenting, Clinically Staged Hodgkin's Patients : The Gruppo Italiano per lo Studio dei Linfomi Experience. / Gobbi, Paolo G.; Pieresca, Carlo; Frassoldati, Antonio; Carotenuto, Mario; Di Renzo, Nicola; La Sala, Antonio; Bertè, Raffaella; Avanzini, Paolo; Federico, Massimo; Silingardi, Vittorio; Ascari, Edoardo.

In: Journal of Clinical Oncology, Vol. 14, No. 2, 02.1996, p. 527-533.

Research output: Contribution to journalArticle

Gobbi, PG, Pieresca, C, Frassoldati, A, Carotenuto, M, Di Renzo, N, La Sala, A, Bertè, R, Avanzini, P, Federico, M, Silingardi, V & Ascari, E 1996, 'Vinblastine, Bleomycin, and Methotrexate Chemotherapy Plus Extended-Field Radiotherapy in Early, Favorably Presenting, Clinically Staged Hodgkin's Patients: The Gruppo Italiano per lo Studio dei Linfomi Experience', Journal of Clinical Oncology, vol. 14, no. 2, pp. 527-533.
Gobbi, Paolo G. ; Pieresca, Carlo ; Frassoldati, Antonio ; Carotenuto, Mario ; Di Renzo, Nicola ; La Sala, Antonio ; Bertè, Raffaella ; Avanzini, Paolo ; Federico, Massimo ; Silingardi, Vittorio ; Ascari, Edoardo. / Vinblastine, Bleomycin, and Methotrexate Chemotherapy Plus Extended-Field Radiotherapy in Early, Favorably Presenting, Clinically Staged Hodgkin's Patients : The Gruppo Italiano per lo Studio dei Linfomi Experience. In: Journal of Clinical Oncology. 1996 ; Vol. 14, No. 2. pp. 527-533.
@article{2c55025496ca4752b381a7c740e15fef,
title = "Vinblastine, Bleomycin, and Methotrexate Chemotherapy Plus Extended-Field Radiotherapy in Early, Favorably Presenting, Clinically Staged Hodgkin's Patients: The Gruppo Italiano per lo Studio dei Linfomi Experience",
abstract = "Purpose: To ascertain whether vinblastine, bleomycin, and methotrexate (VBM) (CT) combined with extended-field radiotherapy (EF RT) is effective enough to spare laparotomy in early, favorably presenting Hodgkin's disease (HD) patients. Patients and Methods: Fifty patients with clinical stage IA or IIA HD with favorable histology and no bulky masses entered a prospective multicenter study started in January 1988. The median follow-up time was 38 months. Results: All patients achieved a complete remission (CR). Five relapsed after 3 to 40 months and underwent successful salvage therapy. The actuarial remission rate was 0.89{\%} at 3 years and 0.82{\%} at 5 years. Two patients died in CR: one of severe pulmonary toxicity, the other of a second neoplasia (adenocarcinoma of the lung), 2 and 43 months after the end of therapy, respectively. The hematologic toxicity recorded during VBM CT was mild on the whole. Major toxicity was represented by pulmonary side effects and neurologic symptoms. Multiple regression analysis demonstrated that pulmonary toxicity was significantly related only to the amount of RT delivered to the mediastinum and not to the relative dose of bleomycin, to the dose-intensities of the three drugs in the regimen, or to patient age or sex. The same statistical technique showed that the only clinical factor related to grade of neurotoxicity was vinblastine dosage. Conclusion: VBM CT combined with EF RT is an effective treatment for early, clinically staged, favorable HD patients. However, the toxicity of this combination suggests that certain modifications should be evaluated.",
author = "Gobbi, {Paolo G.} and Carlo Pieresca and Antonio Frassoldati and Mario Carotenuto and {Di Renzo}, Nicola and {La Sala}, Antonio and Raffaella Bert{\`e} and Paolo Avanzini and Massimo Federico and Vittorio Silingardi and Edoardo Ascari",
year = "1996",
month = "2",
language = "English",
volume = "14",
pages = "527--533",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Vinblastine, Bleomycin, and Methotrexate Chemotherapy Plus Extended-Field Radiotherapy in Early, Favorably Presenting, Clinically Staged Hodgkin's Patients

T2 - The Gruppo Italiano per lo Studio dei Linfomi Experience

AU - Gobbi, Paolo G.

AU - Pieresca, Carlo

AU - Frassoldati, Antonio

AU - Carotenuto, Mario

AU - Di Renzo, Nicola

AU - La Sala, Antonio

AU - Bertè, Raffaella

AU - Avanzini, Paolo

AU - Federico, Massimo

AU - Silingardi, Vittorio

AU - Ascari, Edoardo

PY - 1996/2

Y1 - 1996/2

N2 - Purpose: To ascertain whether vinblastine, bleomycin, and methotrexate (VBM) (CT) combined with extended-field radiotherapy (EF RT) is effective enough to spare laparotomy in early, favorably presenting Hodgkin's disease (HD) patients. Patients and Methods: Fifty patients with clinical stage IA or IIA HD with favorable histology and no bulky masses entered a prospective multicenter study started in January 1988. The median follow-up time was 38 months. Results: All patients achieved a complete remission (CR). Five relapsed after 3 to 40 months and underwent successful salvage therapy. The actuarial remission rate was 0.89% at 3 years and 0.82% at 5 years. Two patients died in CR: one of severe pulmonary toxicity, the other of a second neoplasia (adenocarcinoma of the lung), 2 and 43 months after the end of therapy, respectively. The hematologic toxicity recorded during VBM CT was mild on the whole. Major toxicity was represented by pulmonary side effects and neurologic symptoms. Multiple regression analysis demonstrated that pulmonary toxicity was significantly related only to the amount of RT delivered to the mediastinum and not to the relative dose of bleomycin, to the dose-intensities of the three drugs in the regimen, or to patient age or sex. The same statistical technique showed that the only clinical factor related to grade of neurotoxicity was vinblastine dosage. Conclusion: VBM CT combined with EF RT is an effective treatment for early, clinically staged, favorable HD patients. However, the toxicity of this combination suggests that certain modifications should be evaluated.

AB - Purpose: To ascertain whether vinblastine, bleomycin, and methotrexate (VBM) (CT) combined with extended-field radiotherapy (EF RT) is effective enough to spare laparotomy in early, favorably presenting Hodgkin's disease (HD) patients. Patients and Methods: Fifty patients with clinical stage IA or IIA HD with favorable histology and no bulky masses entered a prospective multicenter study started in January 1988. The median follow-up time was 38 months. Results: All patients achieved a complete remission (CR). Five relapsed after 3 to 40 months and underwent successful salvage therapy. The actuarial remission rate was 0.89% at 3 years and 0.82% at 5 years. Two patients died in CR: one of severe pulmonary toxicity, the other of a second neoplasia (adenocarcinoma of the lung), 2 and 43 months after the end of therapy, respectively. The hematologic toxicity recorded during VBM CT was mild on the whole. Major toxicity was represented by pulmonary side effects and neurologic symptoms. Multiple regression analysis demonstrated that pulmonary toxicity was significantly related only to the amount of RT delivered to the mediastinum and not to the relative dose of bleomycin, to the dose-intensities of the three drugs in the regimen, or to patient age or sex. The same statistical technique showed that the only clinical factor related to grade of neurotoxicity was vinblastine dosage. Conclusion: VBM CT combined with EF RT is an effective treatment for early, clinically staged, favorable HD patients. However, the toxicity of this combination suggests that certain modifications should be evaluated.

UR - http://www.scopus.com/inward/record.url?scp=0030045571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030045571&partnerID=8YFLogxK

M3 - Article

C2 - 8636767

AN - SCOPUS:0030045571

VL - 14

SP - 527

EP - 533

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -